依普利酮需要注意什么呢？

, Product name: Planep. Eplerenone is a new, highly selective aldosterone receptor blocker that can be used to treat heart failure, hypertension, and coronary heart disease. With the continuous progress of research, the scope of clinical application of eplerenone is constantly being expanded, and its status in the field of cardiovascular disease treatment is also constantly improving.

Eplerenone is a new type of selective aldosterone receptor antagonist. The pure product is white or off-white crystal. It has stronger aldosterone antagonism than spironolactone and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions and has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. It has fewer adverse reactions and good tolerance. It is a good alternative drug to spironolactone.

What should I pay attention to when taking eplerenone?

The side effects of eplerenone are: Endocrine and metabolic: hyperkalemia ([heart failure, post-myocardial infarction: >5.5meq/L: 16%; ≥6meq/L: 6%, [hypertension, >5.5meq/L: 400mg: 9%; dose ≤200mg: ≤1%]), hypertriglyceridemia (1%-15%; dose-related).

Hyperkalemia may occur while taking eplerenone; the risk of hyperkalemia is increased with renal impairment, proteinuria, diabetes mellitus, and in patients concurrently taking ACE (angiotensin-converting enzyme) inhibitors, angiotensin II inhibitors, NSAIDs, or moderate CYP3A inhibitors. Monitor closely for hyperkalemia; serum potassium increased dose-related during clinical trials. As hyperkalemia develops, dose reduction or treatment interruption may be necessary. If concomitant treatment with a moderate CYP3A4 inhibitor cannot be avoided, reduce the eplerenone dose. It is contraindicated in patients with potassium greater than 5.5 meq/L at the beginning of treatment.

When evaluating patients with heart failure for treatment, eGFR (epidermal growth factor receptor) should be greater than 30ml/min/1.73m2 or creatinine should be less than or equal to 2.5mg/dL (men) or less than or equal to 2mg/dL (women) with no recent exacerbation, potassium less than 5meq/L and no history of severe hyperkalemia. If blood potassium levels are elevated, close monitoring and management are required.